Rheumatoid Arthritis Drug Candidate Advances to FDA's New Drug Application Program

Rheumatoid Arthritis Drug Candidate Advances to FDA's New Drug Application Program

Indianapolis-based Eli Lilly & Company and Incyte Corp announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of baricitinib, a once-daily oral compound for the treatment of …

(Visited 3 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.